Literature DB >> 23613425

A biodegradable polymersome containing Bcl-xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect.

Hyun-Ouk Kim1, Eunjung Kim, Yonghee An, Jihye Choi, Eunji Jang, Eun Bi Choi, Aastha Kukreja, Myeong-Hoon Kim, Byunghoon Kang, Dong-Joo Kim, Jin-Suck Suh, Yong-Min Huh, Seungjoo Haam.   

Abstract

Combined cancer treatment via co-delivery of siRNAs and an anticancer drug can be a promising strategy due to the synergistic effect of simultaneously minimizing gene/drug administration. In this study, Bcl-xL siRNA and doxorubicin (DOX) are encapsulated into designed methoxy-poly(ethylene glycol)-block-poly(D,L-lactic acid) (mPEG-b-PLA) block copolymer polymersomes (PSomes). A study of the cytotoxicity of Bcl-xL siRNA and DOX co-encapsulated PSomes (CPSomes) shows more inhibited proliferation of MKN-45 and MKN-28 human gastric cancer cell lines than only gene- and drug-loaded ones. Consequently, these results demonstrate that co-delivery of genes and drugs using PSomes results in a synergistic efficacy and indicates the potential of PSomes as efficient nanocarriers for combined cancer therapy.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23613425     DOI: 10.1002/mabi.201200448

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN: 1616-5187            Impact factor:   4.979


  9 in total

Review 1.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

Review 2.  Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.

Authors:  Bo Xiao; Lijun Ma; Didier Merlin
Journal:  Expert Opin Drug Deliv       Date:  2016-07-06       Impact factor: 6.648

Review 3.  From stealthy polymersomes and filomicelles to "self" Peptide-nanoparticles for cancer therapy.

Authors:  Núria Sancho Oltra; Praful Nair; Dennis E Discher
Journal:  Annu Rev Chem Biomol Eng       Date:  2014       Impact factor: 11.059

4.  Incorporation of osteogenic and angiogenic small interfering RNAs into chitosan sponge for bone tissue engineering.

Authors:  Sen Jia; Xinjie Yang; Wen Song; Lei Wang; Kaixiu Fang; Zhiqiang Hu; Zihui Yang; Chun Shan; Delin Lei; Bin Lu
Journal:  Int J Nanomedicine       Date:  2014-11-17

5.  Host Cell Mimic Polymersomes for Rapid Detection of Highly Pathogenic Influenza Virus via a Viral Fusion and Cell Entry Mechanism.

Authors:  Hyun-Ouk Kim; Woonsung Na; Minjoo Yeom; Jihye Choi; Jihye Kim; Jong-Woo Lim; Dayeon Yun; Haejin Chun; Geunseon Park; Chaewon Park; Jeong-Ki Kim; Dae Gwin Jeong; Van Phan Le; Kwangyeol Lee; Jae Myun Lee; Hyoung Hwa Jeong; Daesub Song; Seungjoo Haam
Journal:  Adv Funct Mater       Date:  2018-06-25       Impact factor: 18.808

Review 6.  Nanocarriers for delivery of siRNA as gene silencing mediator.

Authors:  Aideé Morales-Becerril; Liliana Aranda-Lara; Keila Isaac-Olivé; Blanca E Ocampo-García; Enrique Morales-Ávila
Journal:  EXCLI J       Date:  2022-08-01       Impact factor: 4.022

7.  Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Authors:  Sahar Eljack; Stephanie David; Areeg Faggad; Igor Chourpa; Emilie Allard-Vannier
Journal:  Int J Pharm X       Date:  2022-09-06

Review 8.  Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.

Authors:  Priya Yadav; Suresh V Ambudkar; N Rajendra Prasad
Journal:  J Nanobiotechnology       Date:  2022-09-24       Impact factor: 9.429

9.  In vitro antiviral activity of circular triple helix forming oligonucleotide RNA towards Feline Infectious Peritonitis virus replication.

Authors:  Oi Kuan Choong; Parvaneh Mehrbod; Bimo Ario Tejo; Abdul Rahman Omar
Journal:  Biomed Res Int       Date:  2014-02-20       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.